Extended indication Pirfenidone AET is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).
Therapeutic value Possible equal value
Registration phase Positive CHMP opinion

Product

Active substance Pirfenidone
Domain Lung diseases
Reason of inclusion Generic G
Main indication Unknown
Extended indication Pirfenidone AET is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).
Current proprietary name Esbriet (Roche)
Already available biosimilars / generics geen
Proprietary name Pirfenidone AET
Mechanism of action Unknown
Route of administration Oral
Therapeutical formulation Unknown
Budgetting framework Extramural (GVS)
Additional remarks Collagen inhibitors; Cytokine inhibitors Portfoliohouder en fabrikant is AET.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date May 2021
Expected Registration June 2022
Orphan drug No
Registration phase Positive CHMP opinion
Additional remarks Vele patenten geldig, de komende jaren nog allemaal van kracht. Positieve CHMP-opinie verkregen in april 2022.

Therapeutic value

Therapeutic value Possible equal value

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information